---
layout: default
title: Denosumab
parent: Model Prediction Only (L5)
nav_order: 106
evidence_level: L5
indication_count: 2
---

# Denosumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Denosumab: Assessment Report — TxGNN Prediction Data Pending Completion

## One-Sentence Summary

Denosumab is a fully human-derived monoclonal antibody targeting RANKL, which has been internationally approved for the prevention of skeletal-related events in osteoporosis and cancer bone metastases. In the current Evidence Pack, **the TxGNN model has not yet generated any drug repurposing prediction candidates**, and key data such as mechanism of action (MOA) and safety warnings are marked as pending, making it currently **impossible to complete a comprehensive drug repurposing indication assessment**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original approved indications | Not recorded in Evidence Pack (general knowledge: osteoporosis, prevention of skeletal-related events in cancer bone metastases) |
| TxGNN predicted new indications | Not yet generated — prediction workflow pending execution |
| TxGNN prediction score | No data |
| Evidence level | Cannot be assessed |
| Taiwan market status | Not marketed (approval number: 0) |
| Number of approval numbers | 0 |
| Recommended decision | **Hold** |

---

## Drug Background Information

Although `original_moa` is marked as a data gap in the Evidence Pack, the following information is provided based on publicly available pharmacological knowledge:

Denosumab (brand names: Prolia® / Xgeva®) is a fully humanized IgG₂ monoclonal antibody that binds with high affinity to **RANK Ligand (RANKL)**, blocking its interaction with the RANK receptor on the surface of osteoclasts, thereby **inhibiting osteoclast differentiation, activation, and survival**, achieving the therapeutic effect of reducing bone resorption.

Clinical applications of this mechanism include:
- **Prolia**: postmenopausal female osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis
- **Xgeva**: prevention of skeletal-related events in patients with bone metastases from solid tumors; treatment of giant cell tumor of bone

However, formal drug repurposing indication assessment **must be based on TxGNN prediction results**, and currently due to missing prediction data, mechanism-of-action correlation analysis cannot be performed.

---

## Taiwan Market Information

Current Taiwan (TFDA) search results show that Denosumab has **0 approval numbers and a market status of Not marketed**.

> ⚠️ Note: Denosumab has been approved for marketing in most global markets (US FDA, European EMA, Japanese PMDA), and Taiwan's Not marketed status may reflect query scope or data collection issues. It is recommended to re-verify the TFDA query results.

---

## Safety Considerations

Safety warnings and contraindication data in this Evidence Pack have not yet been collected in full.

Please refer to the official package inserts (Prolia® or Xgeva®) for complete safety information. Known important safety considerations include: hypocalcemia, osteonecrosis of the jaw (ONJ), atypical femoral fractures, increased infection risk, and others.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack contains incomplete data—the TxGNN has not yet generated any drug repurposing prediction candidates, mechanism-of-action data is missing (DG002), and safety warnings have also not yet been collected (DG001). Without predicted indications, no evidence assessment or decision analysis can be performed.

**To proceed further, the following data must be completed:**

1. **Execute the TxGNN prediction workflow**: Generate a list of drug repurposing candidate indications for Denosumab (DB06643)
2. **Complete MOA data (DG002)**: Query the formal MOA description through the DrugBank API to facilitate mechanism-of-action correlation analysis
3. **Complete TFDA package insert safety data (DG001)**: Download and parse the TFDA package insert PDF to extract warnings and contraindications (Blocking level, affecting S1 safety initial assessment)
4. **Confirm Taiwan market status**: Re-verify whether TFDA query results correctly reflect the market situation
5. **Supplement original approved indication field**: Only after ensuring the `original_indications` field is correctly populated can a complete From/To indication comparison report be executed

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

